Phio Pharmaceuticals Corp. PHIO
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -23.69%
- 1 year
- -45.86%
- Market cap
- 9.31M
- EPS (ttm)
- -1.29
- Shares out
- 1.06M
- Forward P/E
- 0.07
- YTD return
- -23.69%
- 1-year return
- -45.86%
- Volume
- 75.62K
- Avg volume
- 124.18K
- Open
- 0.78
- Previous close
- 0.80
- Day's range
- 0.75 – 0.8298
- 52-week range
- 0.80 – 1.65
- Beta
- 1.47
5D -0.0587 (-6.83%)
Key statistics
- Enterprise value
- -2.80M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.73M
- Total cash
- 4.70M
- Total debt
- 0
- Return on equity
- -126.86%
- Short % of float
- 6.00%
- 50-day average
- 2.76
- 200-day average
- 4.62
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.54 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -4.59 | -3.62 | +0.97 | +21.13% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -4.23 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -1.53 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -12.87 | -10.26 | +2.61 | +20.28% |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -13.23 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 16, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- phiopharma.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target 
Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio - Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision
Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy - Phio Pharmaceuticals Commences Manufacturing The First Commercial-scale Batch Of PH-762 Drug Substance At Nitto Denko Avecia
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate 
Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event 
Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply
Your note
Sign in to keep a note on PHIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BITTERMAN ROBERT J | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2024 | 17,832 |
| BRADFORD PATRICIA A | Director | Stock Award(Grant) | Sep 10, 2024 | 8,000 |
| CAUWENBERGH GEERT | Director | Stock Award(Grant) | Feb 16, 2023 | 4,235 |
| FERRARA ROBERT L | Director | Stock Award(Grant) | Sep 10, 2024 | 10,000 |
| FREEMAN JONATHAN E PH.D. | Director | Stock Award(Grant) | Sep 10, 2024 | 1,000 |
| KONTULIS CAITLIN | Officer | Stock Award(Grant) | Feb 16, 2023 | 12,494 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 2.38% | 25,131 | 56.04K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 1,685 | 3.76K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.11% | 1,174 | 2.62K | Sep 29, 2024 |
| Nordwand Advisors, LLC | 0.05% | 500 | 1.11K | Sep 29, 2024 |
| Activest Wealth Management | 0.00% | 9 | 20 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 7 | 15 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.41% | 4,290 | 9.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.26% | 2,707 | 6.04K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 1,582 | 3.53K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 4 | 8 | Sep 29, 2024 |